CAYSTON provided results that patients felt through improved respiratory symptoms such as coughing, wheezing, and sputum production

Day 28

CAYSTON significantly improved respiratory symptoms compared to placebo at the end of 28 days of treatment

Change in respiratory symptoms was the primary endpoint of AIR-CF1. Changes in respiratory symptoms were assessed using a patient questionnaire. Click here to review the full study design.

CAYSTON significantly improved respiratory symptoms:

  • Coughing
  • Wheezing
  • Sputum production
Day 42

Respiratory symptom improvement remained above placebo at Day 42

Two weeks after completion of treatment, a difference in respiratory symptoms between treatment groups was still present, though the difference was smaller.